Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial

IMPORTANCE: New therapeutic options for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination therapy in patients with mPDAC. OBJECTIVE: To evaluate the safety and efficacy of the anti–PD-L1 (programmed death-ligand 1) antibody...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: O’Reilly, Eileen M., Oh, Do-Youn, Dhani, Neesha, Renouf, Daniel J., Lee, Myung Ah, Sun, Weijing, Fisher, George, Hezel, Aram, Chang, Shao-Chun, Vlahovic, Gordana, Takahashi, Osamu, Yang, Yin, Fitts, David, Philip, Philip Agop
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6647002/
https://ncbi.nlm.nih.gov/pubmed/31318392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1588
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados